ArticleScientific reports2024
Antimicrobial resistance burden pre and post-COVID-19 pandemic with mapping the multidrug resistance in Egypt: a comparative cross-sectional study.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Five years of wastewater surveillance reveal COVID-19-Associated amplification and seasonal shifts inOne health (Amsterdam, Netherlands) · 2026Article
- Article
- Increased Carbapenem resistance and gene carriage in Pseudomonas aeruginosa clinical isolates after the COVID-19 pandemic in Egypt.Molecular biology reports · 2026Article
- cJun-assisted loading of RelA DNA-binding promotes synergistic lung epithelial antimicrobial responses.iScience · 2026Article
- Dynamic regression forecasting of carbapenem-resistant Klebsiella spp. based on carbapenem consumption with observed data from 2020 to 2023 and projections up to 2029 in a tertiary hospital in Alexandria, Egypt.BMC infectious diseases · 2026Article
- Impact of COVID-19 Pandemic on Antibiotic Resistance Patterns of Common Bacterial Pathogens to Antibiotics in Northern Ghana.Journal of clinical laboratory analysis · 2026Article
- Temporal trends and mortality associated with difficult-to-treat resistance in bloodstream gram-negative bacilli: a retrospective cohort study in Southern Saudi Arabia.Frontiers in cellular and infection microbiology · 2026Article
- Systematic review on genomic insights into antimicrobial resistance in ESKAPE pathogens.African journal of laboratory medicine · 2026Review
- Antimicrobial susceptibility patterns in Jalisco, Mexico: a snapshot of regional resistance (2021-2023).Frontiers in cellular and infection microbiology · 2026Article
- In-hospital antimicrobial use and multidrug-resistant infections among COVID-19 patients in Northern Malaysia (COVAM): a multicentre study.Journal of pharmaceutical policy and practice · 2026Article
- Antimicrobial Resistance in Urinary Tract Infections Among Patients with and Without Renal Comorbidities: A Retrospective Study from Al-Baha, Saudi Arabia.Pathogens (Basel, Switzerland) · 2025Article
- Burden of antimicrobial resistance and estimated economic impact ofNew microbes and new infections · 2025Article
- Non-canonical Metatranscriptomic analysis of COVID-19 and Dengue reveals an expanded microbial and AMR landscape in COVID-19 mortality patients.PLoS pathogens · 2025Article
- Trends in Antimicrobial Resistance at a Greek Tertiary Hospital over a 7-Year Period, Including the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2025Article
- Changes in microbiological characteristics of bloodstream infections before and after the COVID-19 pandemic in a tertiary teaching hospital in Iran.BMC infectious diseases · 2025Article
- Biofilm and Outer Membrane Vesicle Formation in ESKAPE Gram-Negative Bacteria: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Genomic Characterization of Carbapenem-ResistantMicroorganisms · 2025Article
- High Rates of Antimicrobial Resistance and Emergence of High-Risk Clones in Community-Acquired Uropathogenic Escherichia coli.MicrobiologyOpen · 2025Article
- The prevalence and risk of mortality associated with antimicrobial resistance within nosocomial settings-a global systematic review and meta-analysis of over 20,000 patients.EClinicalMedicine · 2025Article
- Predisposing Factors Associated with Third-Generation Cephalosporin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overuse of antibiotics during coronavirus disease 2019 (COVID-19) in an attempt to reduce COVID-19 mortality in the short term may have contributed to long-term mortality from antimicrobial resistance (AMR). The aim of this study was to evaluate the impact of the COVID-19 pandemic on AMR in Egypt and map the distribution of multidrug-resistant (MDR) and extensive drug-resistant (XDR) across Egypt. Through a multicenter cross-sectional study 2430 culture results were collected in 2019 and 2022 pre and post-COVID-19 pandemic in Egypt, including 400 Klebsiella pneumoniae, 760 Escherichia coli, 650 Acinetobacter baumannii, and 620 Methicillin-resistant staphylococcus aureus (MRSA) culture results. MDR and XDR culture results distribution across Egypt was highlighted through the geographic information system. Mixed effect logistic regression models and sub-group analysis were performed according to the type of specimens to test the impact of COVID-19 on resistance. Adjusted analysis demonstrated K. pneumoniae resistance has increased against quinolones and carbapenems (P < 0.001). Resistance of E. coli has increased significantly against imipenem and meropenem. While E.coli susceptibility has increased to cefoxitin, levofloxacin, and ciprofloxacin. A. baumannii resistance has increased more than double against ceftazidime, cefepime, and piperacillin-tazobactam (P < 0.001). MRSA reserved its susceptibility to vancomycin and linezolid. MDR K. pneumoniae and A. baumannii have increased post-COVID-19 from 67% to 94% and from 79% to 98%, respectively (P < 0.001). XDR K. pneumoniae and A. baumannii have increased from 6% to 46%, and from 47% to 69%, respectively (P < 0.001). COVID-19 has changed the profile of AMR in Egypt so that urgent action is required to mitigate this threat and preserve our capacity to face infections in future decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.